Reye syndrome warning
This article was originally published in The Tan Sheet
Executive Summary
Aspirin Foundation of America urges FDA in a July 6 letter to "not propose similar modifications to the aspirin label warning for Reye syndrome as are being proposed for bismuth subsalicylate." The foundation argued that there are fundamental differences between bismuth subsalicylate and aspirin that would not accommodate the same label warning. P&G also recently told FDA that a link between Reye syndrome and non- aspirin salicylates has not been established ("The Tan Sheet" July 12, p. 12)
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning